How much does ribociclib actually help? The numbers explained

Ribociclib, sold as Kisqali, is a CDK4/6 inhibitor tablet used with hormone therapy for hormone receptor positive, HER2-negative breast cancer. It has been tested in several large, well-run trials, so its benefit is better understood than that of many cancer medicines. In advanced or metastatic breast cancer, adding ribociclib to hormone therapy kept the cancer from growing for noticeably longer than hormone therapy alone. In the first large trial, which combined ribociclib with letrozole after menopause, the typical time before the cancer grew was about two years with the combination, compared with about sixteen months with letrozole alone. More importantly, people on ribociclib also lived longer. In that trial, the typical survival time was roughly a year longer with ribociclib, and similar survival gains were seen in trials in premenopausal women and in trials combining ribociclib with fulvestrant. In early breast cancer, ribociclib is taken for three years after surgery with an aromatase inhibitor. Here it lowered the chance of the cancer coming back. The difference in absolute terms was a few people in every hundred over the first few years of follow-up, and research is continuing to see how this changes with longer follow-up. These are averages from trials. Your own benefit depends on your cancer, your stage and your other treatment, so the numbers are a starting point for a conversation rather than a prediction.

The strongest evidence is in advanced disease

In advanced breast cancer, ribociclib is one of the few targeted medicines shown to help people live longer, not only to delay growth on scans.

In early disease, it lowers risk

After surgery, the aim is fewer recurrences. The benefit is real but smaller in absolute terms, because many people would stay well without it.

Averages hide a wide range

Some people stay on ribociclib for many years. For others, the cancer grows sooner.

Trial results are the best guide we have, but they come with limits worth knowing.

Trial patients are selected

People in trials are often fitter, with fewer other illnesses, and are watched very closely. Results in everyday practice can be a little different.

Treatment has moved on

Trials started years ago. Treatments offered after ribociclib stops working have improved since, which may change survival figures in either direction.

Early cancer results are still maturing

Whether the fall in recurrences in early breast cancer leads to longer survival is still being studied.

What this page cannot tell you

It cannot tell you what ribociclib would do for you. Your oncologist can put the trial results next to your own reports and health.

Many people worry that lowering the dose will waste the treatment. The evidence so far is reassuring.

What analyses suggest

Looks back at trial data suggest that people who needed a lower dose because of side effects seemed to gain similar benefit to those who stayed on the full dose.

Staying on treatment matters more

Continuing at a dose you can manage is generally better than stopping altogether because of side effects. Tell your team early rather than struggling on.

Taking doses regularly

Occasional missed doses are not dangerous, but regular skipping may weaken treatment. A phone reminder or pill box helps.